title: Buteyko breathing techniques in asthma: a blinded randomised controlled trial.
abstract: OBJECTIVE
  To evaluate the effect of Buteyko breathing techniques (BBT) in the management of asthma.
  
  
  METHODS
  Prospective, blinded, randomised study comparing the effect of BBT with control classes in 39 subjects with asthma. The study was conducted from January 1995 to April 1995.
  
  
  METHODS
  Subjects recruited from the community, aged 12 to 70 years, with asthma and substantial medication use.
  
  
  METHODS
  Medication use; morning peak expiratory flow (PEF); forced expiratory volume in one second (FEV1); end-tidal (ET) CO2; resting minute volume (MV); and quality of life (QOL) score, measured at three months.
  
  
  RESULTS
  No change in daily PEF or FEV1 was noted in either group. At three months, the BBT group had a median reduction in daily beta 2-agonist dose of 904 micrograms (range, 29 micrograms to 3129 micrograms), whereas the control group had a median reduction of 57 micrograms (range, -2343 micrograms to 1143 micrograms) (P = 0.002). Daily inhaled steroid dose fell 49% (range, -100% to 150%) for the BBT group and 0 (range, -82% to +100%) for the control group (P = 0.06). A trend towards greater improvement in QOL score was noted for BBT subjects (P = 0.09). Initial MV was high and similar in both groups; by three months, MV was lower in the BBT group than in the control group (P = 0.004). ET CO2 was low in both groups and did not change with treatment.
  
  
  CONCLUSIONS
  Those practising BBT reduced hyperventilation and their use of beta 2-agonists. A trend toward reduced inhaled steroid use and better quality of life was observed in these patients without objective changes in measures of airway calibre.
authors.affiliation: Mater Adult Hospital, South Brisbane, QLD. sbowler@mater.org.au
authors.forename: S D
authors.initials: SD
authors.lastname: Bowler
authors.forename: A
authors.initials: A
authors.lastname: Green
authors.forename: C A
authors.initials: CA
authors.lastname: Mitchell
mesh_terms: D000293:Adolescent; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000420:Albuterol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy / Q000628:therapy*; D001993:Bronchodilator Agents / Q000627:therapeutic use; D002648:Child; D003131:Combined Modality Therapy; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D012129:Respiratory Function Tests; D012138:Respiratory Therapy; D000068299:Salmeterol Xinafoate; D013256:Steroids / Q000627:therapeutic use
chemical_list: D000318:Adrenergic beta-Agonists; D001993:Bronchodilator Agents; D013256:Steroids; D000068299:Salmeterol Xinafoate; D000420:Albuterol